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Conformationβ2glycoprotein I (β2GPI) is the major antigen in the antiphospholipid syndrome. It has been shown that
β2GPI can adapt to different conformations, a circular, a S-shaped and a J-shaped conformation. In literature
anticoagulant properties of β2GPI have been indicated, though there is no consensus on how β2GPI exerts a
certain action. This article will ﬁrst review existing data on the conformation of β2GPI. In addition, we will
investigate whether the conformation of β2GPI plays a role in in the proposed anticoagulant activity of
β2GPI. We investigated the effect of native β2GPI and phospholipid-bound β2GPI on thrombin generation
(TG). Native β2GPI was found to have no signiﬁcant effect on the TG regardless of the concentration of tissue
factor. On the contrary, β2GPI preincubated with phospholipids signiﬁcantly inhibited TG triggered with low
TF concentration, suggesting an effect on the intrinsic pathway. This indicates that native β2GPI in circulation
obtains its anticoagulant activity in the presence of anionic phospholipids such as activated blood cells there-
by serving as an inhibitory modulator in hemostasis.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
The antiphospholipid syndrome (APS) is an autoimmune disease
characterized by vascular thrombosis and obstetrical complications,
and serologically by the presence of antiphospholipid antibodies [1].
Other clinical symptoms that can be prominently present are
kidney-faillure, livedo reticularis and neurological signs, though these
have not been accepted as ofﬁcial criteria due to speciﬁcity reasons
[2]. Antiphospholipid antibodies can be detected via three different as-
says as described by the ofﬁcial revised criteria for APS diagnosis;
anti-β2glycoprotein I (β2GPI) antibody assays, anticardiolipin antibody
assays and prolongation of phospholipid-dependent coagulation assays,
preferably dRVVT-or-APTT based assays [3,4]. The major antigen of
these so-called antiphospholipid antibodies has been found to be
β2GPI [5]. β2GPI is an evolutionary well conserved, highly abundant
48 kDa protein consisting of ﬁve short consensus repeat domains
connected by 3 or 4 amino acids that form a ﬂexible linker between
the domains [5]. The ﬁfth domain includes a large positively charged
patch harboring the binding site for anionic phospolipids [6]. Domain I
contains epitope glycine 40- arginine 43 recognized by the subpopula-
tion of autoantibodies that correlate best with thrombotic manifesta-
tions of APS [7–9]. Interestingly, several years ago various studies2GPI, β2glycoprotein I; β2GPI–
rombin generation.
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.
vier OA license.showed that β2GPI harbours anticoagulant activity by inhibiting factor
(F) XII(a) initiated coagulation [10–12]. However, other studies showed
contradicting results and so far no consensus has been reached [13,14].
The last fewyears several studies have beenpublished describing differ-
ent conformations of β2GPI [15–18]. Therefore we decided to investi-
gate whether the conformation of β2GPI has an inﬂuence on the
proposed anticoagulant properties of β2GPI. In this study we will ﬁrst
summarize the previsously published data regarding the conformation
of β2GPI, followed by recent data produced in our laboratory in order
to study the role of β2GPI in coagulation in relation to its conformation.
Different conformations of β2GPI
β2GPI is a protein discovered in 1961 [19,20], consisting of ﬁve
short consensus repeats, also referred as sushi domains [21]. Domains
I, II, III and IV are approximately 60 amino acids in size. Domains III
and IV contain attachment points for four carbohydrate chains mak-
ing up 20% w/w of the total molecular mass of the protein. Domain
V is different from the other four domains and consists of 82 amino
acids including a C-terminal hydrophilic positively charged patch en-
abling β2GPI to bind anionic surfaces such as activated blood cells
[15]. In 1999, 2 independent groups published the crystal structure
of β2GPI [14,15]. Both studies have established β2GPI as a J-shaped
protein with domain I pointing vertically upward from the surface
and domain V with the positive patch projected downward. The up-
ward positioning of domain I is in line with our previous reports in
which we have shown that domain I is the main domain involved in
binding of thrombosis-related antiphospholipid antibodies. In the
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loop, which is thought to be injected into the phospholipid mem-
brane [15]. In the study of Bouma et al. this loop was proven to con-
tain two loose ends indicating that this crystalized form of β2GPI
was cleaved at position 316–317 [14]. Cleaving of β2GPI at these
amino acids results in loss of the phospholipid-binding capacity of
the protein [22].
Although both groups have established the same structure using
crystalization as optic tool, β2GPI has been suggested to adopt other
conformations. A hint towards different conformations was the fail-
ure of isolation of antigen-antibody complexes from the blood of pa-
tients containing anti-β2GPI antibodies. In 2002, Hammel et al. have
shown by small angle X-ray scattering experiments that β2GPI in so-
lution is not J- but S-shaped [16]. Interestingly enough, in this model
epitope G40-R43 on domain I was covered by a carbohydrate chain.
We have shown that this hidden epitope G40-R43 on domain I is re-
sponsible for the binding of thrombosis-related antiphospholipid an-
tibodies [23]. Apparently β2GPI in solution is present in its nativeFig. 1. Open β2GPI dosedependently inhibits the thrombin generation of normal pooled pla
gered in NPP with 0.5 pM TF and 4 μM phospholipids, in the absence or presence of plasma-
in NPP with different concentrations of TF (0.5-1-5 pM) and 4 μM phospholipids, in the abs
by pre-incubation with phospholipids (48 μM) for 15 minutes (B) or by coating of the β2GP
its open conformation (induced by pre-incubationwith phospholipids for 15 minutes)were added
the anticoagulant effect of β2GPI is shown. A-E. Thrombin generation experiments were run in trS-shaped conformation with epitope G40-R43 covered by a carbohy-
drate chain, but can adapt to a J-shaped conformation upon binding to
an anionic surface. Further proof for this hypothesis was given by the
fact that upon cleaving off the carbohydrate chains, anti-β2GPI anti-
bodies do interact with “native” β2GPI [23].
Recently a new chapter has been added to this story. Agar and col-
leagues have published a study in which native β2GPI was found to
adopt a circular conformation [17]. In this study electron microscopy
was used to visualize β2GPI on a special grid. Whether the grid has
any inﬂuence on the conformation of β2GPI is not known. As with
the previous study of Hammel et al. [16], in this study epitope
G40-R43 was also shown to be hidden, this time not by a carbohy-
drate chain but by domain V. Although the resolution did not reveal
its exact contact surface, it seems that domain V with its C-terminal
positive patch was positioned between domain I and II. Upon binding
to negatively charged surfaces (with its positively charged domain V),
the conformation of β2GPI is disturbed [17]. The closed conformation
of β2GPI opens up, exposing the cryptic site within domain I on thesma (NPP) triggered with low concentrations of TF. A. Thrombin generation was trig-
derived β2GPI in the indicated concentrations. B-C. Thrombin generation was triggered
ence or presence of open activated β2GPI (25 μg/ml). Activation of β2GPI was achieved
I on an anionic ELISA plate (C). D. Different concentrations of β2GPI (6.1 to 50 μg/ml) in
. E. The effect of the pre-incubation timewith phospholipids, varying from 0–30 minutes, on
iplicate.
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only binding to anionic phospholipids or to an antibody “opens up”
β2GPI, but also lipopolysaccharides derived from Escherichia Coli
were found to transform β2GPI from a circular to a J-shaped confor-
mation [24]. At this moment it is not known whether β2GPI can
adapt to either a circular, S-shaped or J-shaped conformation or that
all conformations exist and some serve as intermediates.Inﬂuence of different conformations of β2GPI on TG
Given the contradicting results of β2GPI on coagulation and the
discovery of different conformations of β2GPI, we investigated the in-
ﬂuence of both the native plasma conformation of β2GPI as well as
β2GPI bound to phospholipids (which is regarded as the open activat-
ed conformation of β2GPI) on thrombin generation (TG). Indeed,
upon pre-incubation with anionic surfaces such as phospholipids,
β2GPI undergoes a major conformational change from its native
closed, either circular or S-shaped, to an open J-shaped conformation,
resulting in the exposure of a cryptic epitope in domain I [17,25].
Thrombin activity was calculated as a function of time by comparing
the ﬂuorescent signal from the thrombin-generating sample to that
from a known stable concentration of thrombin activity measured si-
multaneously in a parallel sample, as described previously [26].
In theﬁrst set of experiments, TGwas triggered in normal pooledplas-
ma (NPP)with different concentrations of recombinant human tissue fac-
tor (TF), ranging from 0.5-5 pM, in the presence of 4 μM phospholipids,
containing 20 mol% phosphatidylserine, 60 mol% phosphatidylcholine
and 20 mol% phosphatidylethanolamine. Experiments were carried out
in the absence or presence of plasma-derived β2GPI. This native β2GPI
(25 μg/ml) did not inﬂuence the TG initiated with 0.5 pM TF, not even
at a higher concentration (50 μg/ml) (Fig. 1A). To study the effect of
β2GPI in its open conformation, β2GPI was pre-incubated with 48 μM
phospholipids (β2GPI–ph) for 15 minutes before being tested in the TG
assay. In the presence of 5 pM TF, β2GPI–ph (25 μg/ml) did not signiﬁ-
cantly inﬂuence the TG (Fig. 1B; peak (control)=302.6 nM versus peak
(β2GPI)=241.2 nM). However, β2GPI–ph (25 μg/ml) decreased the TGFig. 2. The interaction sites on domain I-II and domain V of β2GPI are quite well conserved
arginine 43 present in all spieces. In domain V both the KNEKK site and other lysines show
in β2GPI have important roles in the function of the protein.initiated by low TF concentrations (0.5-1 pM), as illustrated by a reduced
peak height (Fig. 1B; peak (0.5 pM TF, control)=124.4 nM versus peak
(0.5 pM TF, β2GPI)=51.4 nM; peak (1 pM TF, control)=192.5 nM ver-
sus peak (1 pM TF, β2GPI)=92.4 nM). Alternatively, to obtain β2GPI in
its open J-shaped conformation, β2GPI was coated on an anionic ELISA
plate. Similar as to pre-incubation with β2GPI pre-incubated with phos-
pholipids, the coated β2GPI decreased the TG initiated by low TF concen-
trations (0.5-1 pM) but not by 5 pM TF (Fig. 1C; peak (0.5 pM TF,
control)=231.9 nM versus peak (0.5 pM TF, β2GPI)=73.9 nM; peak
(1 pM TF, control)=266.7 nM versus peak (1 pM TF, β2GPI)=
134.2 nM; peak (5 pM TF, control)=497.3 nM versus peak (5 pM TF,
β2GPI)=460.7 nM).
Subsequently, the dose-dependency of this anti-coagulant effect of
β2GPI–ph, as well as the effect of the pre-incubation time with phos-
pholipids was investigated. TG was initiated with 0.5 pM TF. As illus-
trated in Fig. 1D, the anti-coagulant effect of β2GPI pre-incubated with
phospholipids already appeared at a concentration of 6.1 μg/ml, and a
concentration of 50 μg/ml completely abolished the TG. As to the effect
of the incubation period, increasing incubation times resulted in a fur-
ther decrease in peak height and increase in lag time (Fig. 1E).Discussion
Earlier studies investigating the role of β2GPI in hemostasis have
found contradicting results, regarding the anti- or procoagulant property
of β2GPI. Recently, more insight into the dynamic conformation was
found. β2GPI seems to be able to adopt different conformations de-
pending on its interactionwith an anionic surface; an S-shaped, a circular
and a J-shaped conformation.We studied these new tie-ins in the confor-
mation of β2GPI in relation to a possible effect on coagulation, measured
by TG. Indeed, we have found that β2GPI in its native conformation does
not affect any of the parameters of TG. Preincubationwith phospholipids,
thereby inducing a conformational change from its native to an open
J-shaped conformation, did reveal anticoagulant properties for β2GPI
on TG. Altogether our data suggest the following working hypothesis:
β2GPI in circulation in its native conformation (either S-shaped orbetween different species. In domain I and II the intersection is best conserved, with
extremely good conservation. This evolutionary conservation suggests that both sites
S36 M. Ninivaggi et al. / Thrombosis Research 130 (2012) S33–S36circular) is unable to exert its anticoagulant activity as apparantly the ac-
tivity site is hidden. At the site of vascular damage β2GPI binds to activat-
ed cellular surfaces resulting in a J-shaped conformation. The active site,
suggesting to be an epitope on domain I, is no longer covered resulting in
the inhibition of coagulation. In this hypothesis β2GPI serves as a modu-
lator of coagulation. A role for domain I asmodulator in coagulation is an
appealing hypothesis, especially when realizing that domain I harbours
the epitope G40-R43 responsible for binding to thrombosis-related anti-
bodies. These antibodies might interfere with the anticoagulant proper-
ties thereby causing thrombosis. Future studies need to be done to
study whether this is likely to happen in patients suffering from the
antiphospholipid syndrome.
Interestingly enough it seems that for both proposed native confor-
mations, S-shaped and circular β2GPI, carbohydrate chains play a role
[16,17]. As mentioned before, epitope G40-R43 was shown to be cov-
ered by a carbohydrate chain and upon binding to an anionic surface
this epitope on domain I was accessible for antiphospholipid antibodies
to bind. In the circular conformation the C-terminal part of domain V is
interactingwith the intersection between domain I and II. Both surfaces
are positively charged, indicating that, based on those charges, they
would push each other away. It is likely that the negatively charged car-
bohydrate chain, that is positioned on top of the domain I-II intersec-
tion, serves as glue between domain V and domains I-II.
β2GPI is an evolutionary conserved protein, quite abundantly pres-
ent inmany species. Additionally,β2GPI is well conserved between spe-
cies [27]. If the charges in β2GPI are important for its function, both the
interaction sites on domain I-II and domain V should be quite well con-
served. And indeed, looking at Fig. 2, it can be observed that in domain I
and II the intersection is best conserved, with arginine 43 present in all
spieces. In domain V it was already shown that the KNEKK sitewas con-
served but also other lysines show extremely good conservation. This
evolutionary conservation indicates that both sites in β2GPI have im-
portant roles. The positive charge in domain V is known to be crucial
for phospholipid binding. The conservation in domain I suggest a role
in the physiological activity of β2GPI. Domain I of β2GPI was shown to
bind thrombosis-related antibodies thereby indicating that this well
conserved region has anticoagulant properties.
In conclusion, the newly generated data on the different confor-
mations of β2GPI to which it can adapt has opened new doors to
study the physiological role of β2GPI in hemostasis. Furthermore it
might also help to further characterize the prothrombotic effects of
antiphospholipid antibodies. We have found in vitro proof for β2GPI
to be involved as anticoagulant agent, only when bound to phospho-
lipids indicating a major role for the conformation of β2GPI. Future
studies are needed to elucidate the exact role of β2GPI in hemostasis.
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